동물용 의약품 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Animal Drugs Market reached USD 43.3 billion in 2024 and is projected to register a CAGR of 6.1% from 2025 to 2034. The market growth is driven by a combination of rising pet ownership, increasing demand for livestock healthcare, and advancements in veterinary medicine. As more people embrace pets as companions, the need for high-quality pharmaceuticals to address a wide range of health conditions is surging.

Likewise, the livestock industry is witnessing a growing emphasis on disease prevention and productivity enhancement, fueling demand for specialized drugs. The rising prevalence of chronic diseases in animals, including arthritis, diabetes, and cardiovascular disorders, is pushing veterinary expenditures higher, prompting the development of more effective treatment options. Increasing awareness about preventive care, coupled with regulatory approvals for innovative veterinary pharmaceuticals, is further accelerating market growth. With ongoing R&D efforts and improved accessibility to veterinary care, the industry is poised for continued expansion.

Pharmaceutical innovations, in line with improved distribution networks, are making animal drugs more accessible across regions. Governments and private organizations are actively supporting veterinary research, leading to the introduction of advanced therapeutics designed to minimize recovery time and enhance overall animal well-being. Additionally, a surge in pet insurance coverage is encouraging pet owners to invest in high-quality medications, ensuring better treatment adherence.

The drugs segment led the market in 2024 with USD 23.8 billion, dominating due to its essential role in treating infections, inflammation, and parasitic infestations. Veterinary pharmaceuticals are increasingly being formulated to provide targeted treatment, reducing side effects and improving efficacy. The rising incidence of zoonotic diseases is also reinforcing the demand for advanced medications, prompting pharmaceutical companies to invest in cutting-edge research. Pet owners are becoming more proactive about their animals' health, opting for prescription medications that offer faster recovery and long-term benefits. Growing concerns over antimicrobial resistance are driving the adoption of alternative treatments, including probiotics and immunomodulators, further diversifying the drug landscape.

Companion animals accounted for 59.2% of the market share in 2024, reflecting the increasing number of households adopting pets and prioritizing their medical care. Rising disposable income, coupled with an emotional attachment to pets, is leading to higher veterinary spending, particularly on specialized medications. The demand for preventative treatments, including vaccines and nutritional supplements, is surging as pet owners seek to enhance their animals' longevity and quality of life. Technological advancements in veterinary diagnostics are also playing a key role in the segment's growth, enabling early disease detection and personalized treatment approaches.

North America accounted for 41.4% of the market share in 2024, maintaining its dominance due to high pet ownership rates and a well-established veterinary healthcare system. The region's significant livestock industry continues to drive demand for pharmaceuticals aimed at improving herd health and productivity. Expanding research initiatives, combined with growing regulatory support for innovative veterinary treatments, are reinforcing industry growth. The increasing availability of advanced treatment options, such as biologics and gene-based therapies, is shaping the future of animal healthcare, ensuring sustained demand for pharmaceuticals across the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of animal diseases
    • 3.2.1.2 Growing focus on livestock productivity
    • 3.2.1.3 Surging demand for pet insurance policies
    • 3.2.1.4 Growing government initiatives and support towards animal welfare
    • 3.2.1.5 Intensified R&D activities drive advancements in veterinary medicine
    • 3.2.1.6 Expanding online veterinary pharmacies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects and drug recalls
    • 3.2.2.2 High cost associated with animal drugs development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Policy landscape
• 3.6 Product pipeline analysis
• 3.7 Investor overview
• 3.8 GAP analysis
• 3.9 Consumer behaviour trends
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Antiparasitic
  • 5.2.2 Anti-inflammatory
  • 5.2.3 Anti-infectives
  • 5.2.4 Corticosteroids
  • 5.2.5 Tranquilizers
  • 5.2.6 Cardiovascular drugs
  • 5.2.7 Gastrointestinal drugs
• 5.3 Vaccines
  • 5.3.1 Modified live vaccines (MLV)
  • 5.3.2 Killed inactivated vaccines
  • 5.3.3 Recombinant vaccines
• 5.4 Medicated feed additives
  • 5.4.1 Antibiotics
  • 5.4.2 Vitamins
  • 5.4.3 Amino acids
  • 5.4.4 Enzymes
  • 5.4.5 Antioxidants
  • 5.4.6 Prebiotics and probiotics
  • 5.4.7 Minerals
  • 5.4.8 Other medicated feed additives

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
  • 6.2.1 Dogs
  • 6.2.2 Cats
  • 6.2.3 Horses
  • 6.2.4 Other companion animals
• 6.3 Livestock animals
  • 6.3.1 Poultry
  • 6.3.2 Swine
  • 6.3.3 Cattle
  • 6.3.4 Fish
  • 6.3.5 Other livestock animals

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Topical
• 7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospital pharmacies
• 8.3 E-commerce
• 8.4 Retail pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Poland
  • 9.3.7 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Taiwan
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 GCC Countries
  • 9.6.3 Israel

Chapter 10 Company Profiles

• 10.1 Agrolabo
• 10.2 Boehringer Ingelheim International
• 10.3 Ceva Santé Animale
• 10.4 Chanelle Pharma
• 10.5 Dechra Pharmaceuticals
• 10.6 Durvet
• 10.7 Elanco Animal Health
• 10.8 Endovac Animal Health
• 10.9 HIPRA
• 10.10 Indian Immunologicals
• 10.11 Merck
• 10.12 Norbrook
• 10.13 Neogen Corporation
• 10.14 Symrise
• 10.15 Vetoquinol
• 10.16 Virbac
• 10.17 Zoetis